UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
| N/A |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.02 | Unregistered Sales of Equity Securities |
Issuance of Common Stock Pursuant to Offering Statement
On April 28, 2023, Vivos, Inc. (the “Company”) completed the sale to investors of 8,000,000 shares of its common stock, par value $0.001 per share (“Common Stock”), pursuant to its Regulation A+ offering being conducted on a “best efforts” basis under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities Act”) (the “Offering”). The Offering is being conducted pursuant to the Company’s offering statement on Form 1-A, originally filed with the Securities and Exchange Commission (“SEC”) on September 1, 2021, as amended (the “Offering Statement”), which was qualified by the SEC on September 15, 2021; further amended and qualified on October 17, 2022. The Offering resulted in gross proceeds to the Company of $640,000. Proceeds from the sale of Common Stock in connection with the Offering will be used for general working capital purposes.
Please see the Offering Statement for additional details regarding the Offering, including the terms of the Common Stock being offered.
As noted above, the issuance of the Common Stock was made in reliance upon an exemption from registration provided under Regulation A+ pursuant to Section 3(6) of the Securities Act.
Upon issuance of the shares of Common Stock in connection with the Offering described above, the Company will have 370,541,528 million shares of Common Stock issued and outstanding,
Issuance of Warrants
On April 28, 2023, the Company issued to certain accredited investors, in consideration of an aggregate of $10,665, (i) warrants to purchase 2,665,000 shares of its Common Stock (“Series A-1 Warrants”), which Series A-1 Warrants expire, if not previously exercised, on December 31, 2023, and are exercisable for Common Stock at $.01 per share; and (ii) warrants to purchase 8,000,000 shares of Common Stock (“Series B-1 Warrants”), which Series B1-1Warrants, expire, if not previously exercised, on June 30, 2026, and are exercisable for Common Stock at $.10 per share. The Series A-1 Warrants and Series B-1 Warrants were issued pursuant to Regulation D under the Securities Act and the rules and regulations thereunder.
| Item 8.01 | Other Events |
See Item 3.02 above.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 2, 2023 | VIVOS INC. | |
| By: | /s/ Michael Korenko | |
| Name: | Michael Korenko | |
| Title: | Chief Executive Officer | |